FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062373072> ?p ?o ?g. }

• W2062373072 endingPage "3750" @default.
• W2062373072 startingPage "3743" @default.
• W2062373072 abstract "Abstract The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points. We assessed the prognostic impact of response on time-to-event parameters in the intent-to-treat population. Patients received nine 6-week cycles of treatment. Time to progression, time to next therapy, and treatment-free interval were associated with quality of response. When European Group for Blood and Marrow Transplantation criteria were used, complete response (CR) was associated with significantly longer time to progression (hazard ratio [HR] = 0.45, P = .004), time to next therapy (HR = 0.46, P = .0004), and treatment-free interval (HR = 0.38, P < .0001) versus partial response, but there was no significant difference in overall survival (HR = 0.87, P = .54); similar differences were seen with CR versus very good partial response by uniform criteria. Quality of response improved with prolonged VMP treatment, with 28% of CRs achieved during cycles 5-9. CR duration appeared similar among patients with “early” (cycles 1-4) and “late” CRs (cycles 5-9) and among patients receiving 9 versus < 9 cycles of bortezomib within VMP. These results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response. This study is registered at http://www.clinicaltrials.gov as NCT00111319." @default.
• W2062373072 created "2016-06-24" @default.
• W2062373072 creator A5001068881 @default.
• W2062373072 creator A5002061358 @default.
• W2062373072 creator A5019718106 @default.
• W2062373072 creator A5020989412 @default.
• W2062373072 creator A5025908450 @default.
• W2062373072 creator A5029035458 @default.
• W2062373072 creator A5029159537 @default.
• W2062373072 creator A5029726728 @default.
• W2062373072 creator A5033573338 @default.
• W2062373072 creator A5043526996 @default.
• W2062373072 creator A5049970120 @default.
• W2062373072 creator A5058355502 @default.
• W2062373072 creator A5059967673 @default.
• W2062373072 creator A5071926851 @default.
• W2062373072 creator A5075621971 @default.
• W2062373072 creator A5082309872 @default.
• W2062373072 creator A5087353636 @default.
• W2062373072 creator A5090790045 @default.
• W2062373072 date "2010-11-11" @default.
• W2062373072 modified "2023-10-14" @default.
• W2062373072 title "Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone" @default.
• W2062373072 cites W1914496726 @default.
• W2062373072 cites W1978377409 @default.
• W2062373072 cites W1978833579 @default.
• W2062373072 cites W1983597383 @default.
• W2062373072 cites W1990372450 @default.
• W2062373072 cites W1991660588 @default.
• W2062373072 cites W2012843756 @default.
• W2062373072 cites W2016038211 @default.
• W2062373072 cites W2019612632 @default.
• W2062373072 cites W2028150271 @default.
• W2062373072 cites W2044436186 @default.
• W2062373072 cites W2056206654 @default.
• W2062373072 cites W2066108041 @default.
• W2062373072 cites W2066295909 @default.
• W2062373072 cites W2066800926 @default.
• W2062373072 cites W2076028786 @default.
• W2062373072 cites W2096207943 @default.
• W2062373072 cites W2102591890 @default.
• W2062373072 cites W2103289287 @default.
• W2062373072 cites W2108235071 @default.
• W2062373072 cites W2111650326 @default.
• W2062373072 cites W2134592456 @default.
• W2062373072 cites W2136256331 @default.
• W2062373072 cites W2148758597 @default.
• W2062373072 cites W2150254829 @default.
• W2062373072 cites W2151512626 @default.
• W2062373072 cites W2153596485 @default.
• W2062373072 cites W2160635879 @default.
• W2062373072 cites W2163129932 @default.
• W2062373072 cites W2163941973 @default.
• W2062373072 cites W2313913420 @default.
• W2062373072 cites W2524582978 @default.
• W2062373072 cites W2584457840 @default.
• W2062373072 cites W3145716452 @default.
• W2062373072 cites W4211082074 @default.
• W2062373072 cites W4236730981 @default.
• W2062373072 cites W4376542883 @default.
• W2062373072 doi "https://doi.org/10.1182/blood-2010-03-275800" @default.
• W2062373072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20628153" @default.
• W2062373072 hasPublicationYear "2010" @default.
• W2062373072 type Work @default.
• W2062373072 sameAs 2062373072 @default.
• W2062373072 citedByCount "98" @default.
• W2062373072 countsByYear W20623730722012 @default.
• W2062373072 countsByYear W20623730722013 @default.
• W2062373072 countsByYear W20623730722014 @default.
• W2062373072 countsByYear W20623730722015 @default.
• W2062373072 countsByYear W20623730722016 @default.
• W2062373072 countsByYear W20623730722017 @default.
• W2062373072 countsByYear W20623730722018 @default.
• W2062373072 countsByYear W20623730722019 @default.
• W2062373072 countsByYear W20623730722020 @default.
• W2062373072 countsByYear W20623730722021 @default.
• W2062373072 countsByYear W20623730722022 @default.
• W2062373072 crossrefType "journal-article" @default.
• W2062373072 hasAuthorship W2062373072A5001068881 @default.
• W2062373072 hasAuthorship W2062373072A5002061358 @default.
• W2062373072 hasAuthorship W2062373072A5019718106 @default.
• W2062373072 hasAuthorship W2062373072A5020989412 @default.
• W2062373072 hasAuthorship W2062373072A5025908450 @default.
• W2062373072 hasAuthorship W2062373072A5029035458 @default.
• W2062373072 hasAuthorship W2062373072A5029159537 @default.
• W2062373072 hasAuthorship W2062373072A5029726728 @default.
• W2062373072 hasAuthorship W2062373072A5033573338 @default.
• W2062373072 hasAuthorship W2062373072A5043526996 @default.
• W2062373072 hasAuthorship W2062373072A5049970120 @default.
• W2062373072 hasAuthorship W2062373072A5058355502 @default.
• W2062373072 hasAuthorship W2062373072A5059967673 @default.
• W2062373072 hasAuthorship W2062373072A5071926851 @default.
• W2062373072 hasAuthorship W2062373072A5075621971 @default.
• W2062373072 hasAuthorship W2062373072A5082309872 @default.
• W2062373072 hasAuthorship W2062373072A5087353636 @default.
• W2062373072 hasAuthorship W2062373072A5090790045 @default.
• W2062373072 hasBestOaLocation W20623730721 @default.
• W2062373072 hasConcept C126322002 @default.

• next